TaVNS Application Timing During Robotic Sensorimotor Task
Launched by OLIVIER LAMBERCY · Feb 28, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Overview:
This study focuses on the potential of transcutaneous auricular Vagus Nerve Stimulation (taVNS) in motor neurorehabilitation for conditions like Parkinson's disease, traumatic brain injury, spinal cord injury, and stroke. taVNS, approved for various neurological conditions and known for its safety, activates neuromodulators contributing to plasticity and motor learning. However, the optimal stimulation parameters, especially timing during movement, are not fully explored.
Study Goals:
Primary Objective: To assess the feasibility and effects of different taVNS timing protocols i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy participants above 18 years of age and able to provide informed consent and understand the study requirements
- Exclusion Criteria:
- • Individuals with major untreated depression, major cognitive and/or communication deficits, and major comprehension and/or memory deficits that may interfere with the informed consent process, task-specific practice, or communication of adverse events will be excluded from the study.
- • Neurological conditions such as epilepsy, participation in any other research trial, pregnancy, use of implanted electrical devices, and use of medication or procedure that interferes with vagal functions.
- • Pregnancy or trying to get pregnant.
About Olivier Lambercy
Olivier Lambercy is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong focus on ethical practices and regulatory compliance, Mr. Lambercy leads a team of experienced professionals who design, implement, and manage clinical trials across various therapeutic areas. His expertise in fostering collaborations with healthcare institutions and regulatory bodies ensures the efficient progression of trials, while maintaining the highest standards of patient safety and data integrity. Through a patient-centered approach, Olivier Lambercy aims to contribute significantly to the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported